American Society of Clinical Oncology

Roche’s Tecentriq, chasing Merck’s Keytruda, nabs another nod in all-important lung cancer | FiercePharma | 12/4/2019

… Keytruda in tandem with Eli Lilly’s chemotherapy Alimta and platinum chemo cut the risk of death by half in first-line nonsquamous NSCLC. In an update of that Keynote-189 trial at this year’s American Society of Clinical Oncology meeting, Merck showed patients on the Keytruda regimen lived a median 22 months compared with 10.7 months for those on chemo alone. As the leader in NSCLC, Keytruda also boasts approval …

Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S. | PR Newswire | 12/2/2019

… exist between the biosimilar product and Herceptin in terms of safety, purity and potency. Long-term results of the landmark HERITAGE study including overall survival data at 36 months were presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Hope S. Rugo , professor of medicine at the University of California, San Francisco , and lead author of the HERITAGE study commented: “Trastuzumab-dkst (Ogivri) has many firsts …

Follow American Society of Clinical Oncology:    

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology . Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow: bladder. http://gco.iarc.fr/tomorrow . View source version on businesswire.com : https://www.businesswire.com …

ASCO Launches New Payment Reform Model to Transform Cancer Care Delivery and Enhance the Quality of Patient Care | 12/2/2019

The American Society of Clinical Oncology (ASCO) released today a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring that patients with cancer have access to high-quality, high-value care. The updated model reflects lessons learned from previous demonstration programs, including a PCOP pilot in New Mexico. Read more …

Outlook on the World’s Skin Cancer Diagnostics and Therapeutics Market, 2019-2024: Growth, Trends & Projections - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | Business Wire | 11/29/2019

DUBLIN–(BUSINESS WIRE)–Nov 29, 2019– The “Skin Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com ‘s offering. The global skin cancer diagnostics and therapeutics market are expected to witness a CAGR of 10.4% over the forecast period. Certain factors driving the market growth include increasing incidence of skin cancer, extensive R&D pipelines, and rising awareness about skin cancer. Skin …

Standard operating procedure for curation and clinical interpretation of variants in cancer | 11/29/2019

… give specific guidance for the curation of each of the model’s elements, and detail how specific guidelines and variant classification systems such as those provided by the American College of Medical Genetics (ACMG), the American Society of Clinical Oncology (ASCO) and the Association for Molecular Pathology (AMP) [ 10 , 11 ] are utilized during curation. We previously reported the release of the Clinical Interpretation of Variants in Cancer (CIViC) knowledgebase ( www.civicdb.org ) [ 12 …

Black men with early-stage prostate cancer can do active surveillance | 11/28/2019

… and thus are low risk. Radical treatments aren’t necessarily beneficial in these cases; instead, these men can be monitored through “active surveillance,” the standard of care recommended by national cancer organizations such as the American Society of Clinical Oncology . In this approach, men diagnosed with early-stage disease receive regular PSA (prostate-specific antigen) testing, biopsies and digital-rectal exams to keep tabs on their cancer. Active surveillance is different …

AmeriLife Partners with Wamberg Genomic Advisors to Provide Access to Cancer Guardian, Innovative Cancer Support Services | PR Newswire | 11/26/2019

… in their lifetime according to the British Journal of Cancer By 2030, cancer is expected to surpass heart disease as the 1 cause of death in the U.S. according to a report by the American Society of Clinical Oncology Cancer is the 2 nd leading condition impacting healthcare spend as reported in IFEPB Workplace Wellness Survey On average, 1 in 7 cancer cases are misdiagnosed 80% of cancers are treated …

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy | Blood Advances | American Society of Hematology | 11/26/2019

… The International Society for Thrombosis and Haemostasis (ISTH) suggests that the use of edoxaban or rivaroxaban is acceptable in cancer patients with acute VTE, low bleeding risk, and no drug-drug interactions. 9 The American Society of Clinical Oncology (ASCO) recommendations are similar, with a strong recommendation for using initial anticoagulation with LMWH, unfractionated heparin (UFH), fondaparinux, or rivaroxaban for 5 to 10 days followed by LMWH, edoxaban, or rivaroxaban …

ASCO Launches Update to the Patient-Centered Oncology Payment Model | 11/26/2019

ASCO Launches Update to the Patient-Centered Oncology Payment Model November 26, 2019 JCP Editors The American Society of Clinical Oncology (ASCO) announced today that it is rolling out a major update to its Patient-Centered Oncology Payment (PCOP) model – an alternative payment model designed to support transformation in cancer care delivery and reimbursement while providing patients with high-quality, high-value cancer care. PCOP: A Community-Based Oncology Medical …

DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM | PR Newswire | 11/25/2019

… more than three months, or approximately 47%, over historical published results from the current standard of care. We look forward to providing subsequent updates in 2020 at the American Association for Cancer Research and American Society of Clinical Oncology conferences.” The Company’s current cash resources are expected to be sufficient to fund the Company’s planned operations into the fourth quarter of calendar year 2020, and to allow for funding to …

Mary-Claire King, PhD, Joins the New York Genome Center as Senior Associate Core Member | PR Newswire | 11/25/2019

… editorial boards or reviewing panels of many publications, including Science and Nature. Dr. King’s exceptional research contributions have been recognized by numerous awards and prizes, including: The Paul Ehrlich and Ludwig Darmstaedter Prize, the American Society of Clinical Oncology Basic Science Award, the American Cancer Society Medal of Honor for Clinical Research, the Weizmann Institute Award for Women and Science, the Gruber Prize in Genetics, the Pearl Meister Greengard Prize …

ACR Leverages AMA Representation to Advance Rheumatology Issues | 11/22/2019

… and discount reports and disclosures available to the public and the inclusion of required public reporting of rebates and discounts by PBMs in federal and state PBM legislation. Resolution 813, co-sponsored by the American Society of Clinical Oncology (ASCO), is now part of AMA policy and its advocacy agenda. ad goes here:advert-1 The ACR also helped lead an ASCO-authored resolution on step therapy that was passed …

Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients | 11/21/2019

… a single institutional retrospective study conducted for 13 years. The patients were treated at Tokai University Hospital in Kanagawa, Japan. The treatments were multiple line treatments, and chemotherapies were fully continued according to the American Society of Clinical Oncology (ASCO) guidelines, the National Comprehensive Cancer Network (NCCN) guidelines or the Japan Lung Cancer Society guidelines. Oligometastases, which include oligoreccurences, were considered to control with radiation and/or surgery if patients …

Belong.Life Expands to South Africa, Broadens Global Impact | PR Newswire | 11/20/2019

… algorithm and artificial intelligence (AI) to deliver customized content for each user. Additionally, data from the Belong.Life platform has been used to support international research projects recognized by the global oncology community, including the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). “While breast cancer is common all around the world, gaps in education, lack of support and access to medical professionals persist,” said …

Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations | PR Newswire | 11/20/2019

… skipping alterations detected by liquid biopsy (LBx) or tissue biopsy (TBx) across different lines of treatment. Results from the interim analysis of the VISION study were presented in an oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting 6 and the 2019 Japan Society of Medical Oncology (JSMO) Annual Meeting. 7 The use of both LBx and TBx to identify patients for the VISION study is …

Mainstreaming Alternative and Complementary Medicine | 11/20/2019

… If a nonmainstream practice is used together with conventional medicine, it’s considered “complementary.” If a nonmainstream practice is used in place of conventional medicine, it’s considered “alternative.” According to a 2018 survey by the American Society of Clinical Oncology , nearly 40% of people in the U.S. believe that cancer can be cured by alternative therapies alone. 4 This belief can be deadly: Patients who forgo conventional cancer treatment and opt …

Janssen Receives EU Marketing Authorisation for Darzalex®▼(daratumumab) in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible | Business Wire | 11/19/2019

… agent daratumumab. Press release August 30, 2012. Available at: https://www.jnj.com/media-center/press-releases/janssen-biotech-announces-global-license-and-development-agreement-for-investigational-anti-cancer-agent-daratumumab Last accessed November 2019. 18 American Society of Clinical Oncology . Multiple myeloma: introduction. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/introduction Last accessed November 2019. 19 GLOBOCAN 2018. Cancer Today Population Factsheets: Europe Region. Available at: https://gco.iarc.fr/today/data …

ASCO Guidelines on VTE Add New Oral Agents | 11/19/2019

Updated venous thromboembolism (VTE) guidelines issued by the American Society of Clinical Oncology (ASCO) now include the use of direct oral anticoagulants (DOACs) for patients with cancer as a preventive measure against VTE recurrence.It is common for unsuspected blood clots to be detected at the time of routine baseline staging imaging, such as during CT scans, said Lyman. “Those patients should be treated for their VTE with therapeutic doses of …

Early Signs of Cancer Men Shouldn’t Ignore | 11/18/2019

… weight then it’s time to make a doctor appointment. “One cause is cancer, especially in the mouth, throat, or esophagus. Cancer growing in these parts of the body may narrow these passages,” reports the American Society of Clinical Oncology . Your doctor will likely have you undergo testing that can involve a CT or swallow study. Dysphagia caused by cancer will worsen over time as the cancer grows, causing the esophagus …

Food and Drug Administration

Trump’s New FDA Commissioner Nominee Advances in Senate | 12/4/2019

0 15 President’s Trump pick to lead the U.S. Food and Drug Administration (FDA) has secured a key vote in a Senate committee, paving a way for him to advance to a full chamber vote … major health advocacy groups including the American Cancer Action Network, American Society of Clinical Oncology and others. For all the latest legislation and FDA news impacting the tobacco industry, click here . TAGS …

Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S. | PR Newswire | 12/2/2019

… vial in order to provide patient dosing and treatment flexibility. Ogivri was the first biosimilar trastuzumab approved by the U.S. Food and Drug Administration (FDA) and unanimously recommended by the FDA Oncologic Drugs Advisory Committee … survival data at 36 months were presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Hope S. Rugo , professor of medicine at the University of California, San Francisco , and lead author …

National Cancer Institute

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping | Fortune | 12/4/2019

… at the renowned MD Anderson Cancer Center in Texas. Currently, another oncologist, Dr. Ned Sharpless, the former director of the National Cancer Institute, serves as the agency’s acting chief. Sharpless took over that interim role … of patient advocacy groups including the American Cancer Action Network, American Society of Clinical Oncology (one of the largest cancer groups in the world), and others. More must-read stories from Fortune : — 2020 Crystal Ball …

David Danforth, MD, Celebrates More Than 45 Years of Professional Excellence | 12/4/2019

… more than 45 years of professional experience to his credit, Dr. Danforth has excelled with the National Institutes of Health’s National Cancer Institute as a senior investigator since 1985 and a senior staff fellow since … as a member of the Society of Surgical Oncology, the American Society of Clinical Oncology, the American Association of Cancer Research, and the American Society of Breast Surgeons. Throughout his career, Dr. Danforth has been …

National Institutes of Health

J. Wayne Meredith, MD, FACS, MCCM, is 2019-2020 ACS President-Elect | The Bulletin | 12/4/2019

… career, Dr. Meredith has been awarded 10 grants for various trauma research studies. He is the principal investigator for a National Institutes of Health (NIH) grant for Integrative Training in Trauma and Regenerative Medicine, as … Newman is a member of the Association of Women Surgeons, American Society of Clinical Oncology, American Society of Breast Surgeons, Society of Surgical Oncology, Society of Black Academic Surgeons, and American Surgical Association, among others …

David Danforth, MD, Celebrates More Than 45 Years of Professional Excellence | 12/4/2019

… the selection process. With more than 45 years of professional experience to his credit, Dr. Danforth has excelled with the National Institutes of Health’s National Cancer Institute as a senior investigator since 1985 and a … as a member of the Society of Surgical Oncology, the American Society of Clinical Oncology, the American Association of Cancer Research, and the American Society of Breast Surgeons. Throughout his career, Dr. Danforth has been …

Biosimilars

Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US - December 3, 2019 - Zacks.com | 12/3/2019

… the branded drug in terms of safety, purity and potency. Notably, the long-term results of the landmark HERITAGE study, including the overall survival data at 36 months, were presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Meanwhile, the FDA recently approved two supplemental Biologics License Applications, expanding the manufacturing capability for Ogivri and Fulphila (biosimilar to Neulasta), which is Mylan and Biocon’s first biosimilar in …

Genomics

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples | Nature | 12/3/2019

… Sawyer, L. R., He, X., Troester, M. A. et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8 , 258 (2007). Google Scholar 12. Costa, R., Shah, A. N., Santa-Maria, C … K. L., Allred, D. C., Cote, R. J. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab …

Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling | Nature | 11/29/2019

… suggested by previous studies. 10 , 11 Cut-off for ER and PR positivity was determined at 1%, according to the Consensus of St. Gallen 2011. 12 HER2 was evaluated as recommended by the American Society of Clinical Oncology/College of American Pathologists. 13 Ki67 proliferation index was assessed on surgical specimens and a minimum of 1000 cells were evaluated. 4 The surrogate of molecular subtypes obtained from ER, PR and …

Institutional Review Board

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples | Nature | 12/3/2019

… A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth … Declaration of Helsinki guidelines, and was approved by the ICM Institutional Review Board (ID number ICM-CRB-2012/04). Samples were provided by ICM biological resource centre (Biobank number BB-0033-00059), following the ethics and legal …

Inadequate Nutrition Coverage in Outpatient Cancer Centers: Results of a National Survey | 11/22/2019

… outpatient cancer center; no criteria were defined for outpatient cancer centers. Study procedures were approved by the Ohio State University Institutional Review Board, and informed consent was obtained from all participants prior to participation. 2.2 … View at Publisher · View at Google Scholar · View at Scopus American Society of Clinical Oncology, “The state of cancer care in America, 2017: a report by the American society of clinical oncology,” Journal of Oncology …

American Medical Association

Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S. | PR Newswire | 12/2/2019

… Long-term results of the landmark HERITAGE study including overall survival data at 36 months were presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Hope S. Rugo , professor of medicine … biosimilar study to be published in the Journal of the American Medical Association. In this context, the HERITAGE study had a unique trial design that not only evaluated objective response rate at week 24 as …

Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S. - GuruFocus.com | 12/2/2019

… Long-term results of the landmark HERITAGE study including overall survival data at 36 months were presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Hope S. Rugo , professor of medicine … biosimilar study to be published in the Journal of the American Medical Association. In this context, the HERITAGE study had a unique trial design that not only evaluated objective response rate at week 24 as …

Clinical Collaboration

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Malvern Daily Record | 12/2/2019

… Genetics, Inc. ( Nasdaq:SGEN ) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

International Agency for Research on Cancer

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow: bladder. http://gco.iarc.fr/tomorrow . View source version on businesswire.com : https://www.businesswire.com/news/home/20191202005357/en/ CONTACT: Seattle Genetics Contacts …

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Malvern Daily Record | 12/2/2019

… American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow: bladder. http://gco.iarc.fr/tomorrow …

CDC

Outlook on the World’s Skin Cancer Diagnostics and Therapeutics Market, 2019-2024: Growth, Trends & Projections - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | Business Wire | 11/29/2019

… increasing at 1.7% and 1.4% per year respectively, as per the data of Federal Centers for Disease Control and Prevention (CDC). Thus, the increasing prevalence of skin cancer is augmenting the growth of the market … Market Share in the Disease Type According to the ASCO (American Society of Clinical Oncology), it is estimated that more than 3 million people in the United States are diagnosed with non-melanoma skin cancer …

Janssen Receives EU Marketing Authorisation for Darzalex®▼(daratumumab) in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible | Business Wire | 11/19/2019

… 7 Daratumumab is believed to induce tumour cell death through multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as well … investigational-anti-cancer-agent-daratumumab Last accessed November 2019. 18 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/introduction Last accessed November 2019. 19 GLOBOCAN 2018. Cancer …

Merck

Roche’s Tecentriq, chasing Merck’s Keytruda, nabs another nod in all-important lung cancer | FiercePharma | 12/4/2019

Merck & Co.’s Keytruda-chemo pairing. Last April, Merck showed Keytruda in tandem with Eli Lilly’s chemotherapy Alimta and platinum chemo cut the risk of death by half in first-line nonsquamous NSCLC. In an update of that Keynote-189 trial at this year’s American Society of Clinical Oncology meeting, Merck showed patients on the Keytruda regimen lived a median 22 months compared with 10.7 months for those on chemo …

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

Weather AP Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer 1 hr ago Save BOTHELL, Wash. & TOKYO–(BUSINESS … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Bristol-Myers Squibb

Roche’s Tecentriq, chasing Merck’s Keytruda, nabs another nod in all-important lung cancer | FiercePharma | 12/4/2019

… of death by half in first-line nonsquamous NSCLC. In an update of that Keynote-189 trial at this year’s American Society of Clinical Oncology meeting, Merck showed patients on the Keytruda regimen lived a … are also eyeing additional shares of the lucrative NSCLC market. Bristol-Myers Squibb has shown that Opdivo plus CTLA4 inhibitor Yervoy and chemo have together beaten out chemo alone at extending survival in first-line …

Outlook on the World’s Skin Cancer Diagnostics and Therapeutics Market, 2019-2024: Growth, Trends & Projections - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | Business Wire | 11/29/2019

… Market Trends Non-melanoma is expected to hold a Significant Market Share in the Disease Type According to the ASCO (American Society of Clinical Oncology), it is estimated that more than 3 million people in … of a number of major players. Companies, like Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., among others, hold the substantial market share in the …

Teva Pharmaceutical

Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US - December 3, 2019 - Zacks.com | 12/3/2019

… term results of the landmark HERITAGE study, including the overall survival data at 36 months, were presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Meanwhile, the FDA recently approved two supplemental … generic business. However, competition is stiffening for EpiPen as rival Teva Pharmaceutical ( TEVA - Free Report ) won FDA approval for the first generic version of Mylan’s EpiPen and EpiPen Jr, which in turn will unfavorably impact …

Seattle Genetics

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

Weather AP Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer 1 hr ago Save BOTHELL, Wash. & TOKYO–(BUSINESS … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Malvern Daily Record | 12/2/2019

Seattle Genetics, Inc. ( Nasdaq:SGEN ) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Amgen

Outlook on the World’s Skin Cancer Diagnostics and Therapeutics Market, 2019-2024: Growth, Trends & Projections - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | Business Wire | 11/29/2019

… Market Trends Non-melanoma is expected to hold a Significant Market Share in the Disease Type According to the ASCO (American Society of Clinical Oncology), it is estimated that more than 3 million people in … and consists of a number of major players. Companies, like Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., among others, hold the substantial market share …

Durable Benefits With Melanoma Combinations | 11/19/2019

… and trametinib with dabrafenib alone. The two trials involved a combined total of 563 patients. As reported at the 2019 American Society of Clinical Oncology (ASCO) meeting, and subsequently in the New England Journal of … Roche. Ribas disclosed relevant relationships with Genentech, Roche, Chugai, Novartis, Amgen, Merck, Bristol-Myers Squibb, Arcus Biosciences, Bioncotech Therapeutics, Compugen, CytomX, Five Prime Therapeutics, FLX Bio, ImaginAb, Kite Pharma, Merus, Regenix, Tango Therapeutics, and PACT …

Thermo Fisher

Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola | 11/23/2019

… determination at diagnosis [ 42 ]. 2.4. Test Procedures Commercially available ELISA assays were used to measure CSF levels of neopterin (Brahms, Thermo Fisher Scientific, Germany) and CXCL-13 (R&D Systems, UK, and RayBiotech, GA, USA … Fluids: Laboratory Examination of Amniotic, Cerebrospinal, Seminal, Serous & Synovial Fluids , American Society of Clinical Oncology, Chicago, IL, USA, 3 edition, 1993. J. Bonnet, Exploitation d’une biobanque de patients atteints de Trypanosomose Humaine Africaine à Trypanosoma …

The precision medicine approach to cancer therapy: part 1 — solid tumours | 11/8/2019

… sponsored NCI-MATCH, NCI-MPACT, ALCHEMIST, Lung-MAP, Pediatric MATCH, Exceptional Responders, Lung Cancer Mutation Consortium (LCMC)-sponsored, and the American Society of Clinical Oncology (ASCO)-sponsored TAPUR (Targeted Agent and Profiling Utilization Registry) clinical … ALK and ROS-1 [82] . The Oncomine Dx Target Test (Thermo Fisher Scientific) based on next-generation sequencing was approved to test for BRAF , ROS-1 and EGFR mutations in these patients [82] , [83] . NGS …

Medidata

Medidata Q&A: reflecting on the first year of Acorn AI | 11/20/2019

… solution. Enter your details here to receive your free whitepaper. Close survey In January 2019, US clinical trial software company Medidata began to move into the AI space with the appointment of former McKinsey partner … publicly, [these include] the publications that came out of the American Society of Clinical Oncology (ASCO), as well as the work that we’ve been doing with the Castleman Disease Collaborative Network in terms of finding …

What will Clinical Research Look Like in 5, 10, 20 Years? Are We Heading to Heaven, Hell or Purgatory? Part 2 of 4 - Saama Technologies | 11/13/2019

… growth strategies, cultivating opportunities, and increasing demand for Saama’s solutions. Prior to joining Saama, Greg spent over five years at Medidata Solutions, a leader in eClinical development software, where he led an integrated marketing team … Summit & Roundtable; International Society of Pharmacoeconomics and Outcomes Research (ISPOR); American Society of Clinical Oncology (ASCO); and the American Heart Association (AHA). He is the author of or cited in over 25 scientific publications. × Jay …

Bristol-Myers

ONcology Rounds - Nashville Medical News | 11/18/2019

… for the fund through Hockey Fights Cancer nights, special auctions and more. Pooled Five-Year Survival Results for Opdivo Released Bristol-Myers Squibb recently announced pooled five-year survival results for Opdivo (nivolumab) in previously … Rehabilitation, American College of Lifestyle Medicine, American Physical Therapy Association, American Society of Clinical Oncology, Canadian Society of Exercise Physiology, Centers for Disease Control and Prevention, Commission on Accreditation for Rehabilitation Facilities, German Union for …

What will Clinical Research Look Like in 5, 10, 20 Years? Are We Heading to Heaven, Hell or Purgatory? Part 2 of 4 - Saama Technologies | 11/13/2019

… the United States, Europe and Asia. Before joining UCB, he was vice president and head of Global Development Operations at Bristol-Myers Squibb, where he led a 1,400-person organization that managed clinical trials from … Summit & Roundtable; International Society of Pharmacoeconomics and Outcomes Research (ISPOR); American Society of Clinical Oncology (ASCO); and the American Heart Association (AHA). He is the author of or cited in over 25 scientific publications. × Jay …

Sarah Cannon Research Institute

Oncology Innovation in Nashville - Nashville Medical News | 11/18/2019

… at Sarah Cannon are using DNA sequencing technology to identify the most effective, personalized treatment for each tumor. At June’s American Society of Clinical Oncology (ASCO) annual meeting, Sarah Cannon researchers presented results of a … availability of testing to oncologists outside of large medical centers. Sarah Cannon Research Institute studies also demonstrate the economic impact of NGS. “From both tissue exhaustion and economic standpoints, studies show it’s a much more …

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature | 10/30/2019

… Sarah Cannon Research Institute; has served in a consulting or advisory capacity for EMD Serono and Fujifilm; has received research funding from 3-V Biosciences, Abbvie, ADC Therapeutics, Aileron, American Society of Clinical Oncology, Amgen, ARMO, AstraZeneca, BeiGene, Bioatla, Biothera, Celldex, Celgene, Ciclomed, Curegenix, Curis, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Exelixis, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Jounce, Kolltan, Loxo, MedImmune, Millennium, Merck, Mirna Therapeutics, the National …

WebMD

Early Signs of Cancer Men Shouldn’t Ignore | 11/18/2019

… in the mouth, throat, or esophagus. Cancer growing in these parts of the body may narrow these passages,” reports the American Society of Clinical Oncology . Your doctor will likely have you undergo testing that can … your doctor take a look says Dr. Marlene Meyers of WebMD . Lymphoma is cancer of the lymphatic system and one of the symptoms that it can present with is swollen lymph nodes. Breath Analysis: A …

Cancer Drug Combos Causing Cost-Effectiveness Headaches | Medscape | 10/4/2019

… four European countries. When they compared monthly drug prices with the clinical effectiveness of each drug, as measured on the American Society of Clinical Oncology Value Framework and the ESMO Magnitude of Clinical Benefit Scale … The National Institute for Health and Care Excellence (NICE). © 2019 WebMD, LLC Send comments and news tips to . Cite this: Liam Davenport. Cancer Drug Combos Causing Cost-Effectiveness Headaches - Medscape - Oct 04, 2019. Authors and …

SVB Leerink

Roche’s Tecentriq, chasing Merck’s Keytruda, nabs another nod in all-important lung cancer | FiercePharma | 12/4/2019

… of death by half in first-line nonsquamous NSCLC. In an update of that Keynote-189 trial at this year’s American Society of Clinical Oncology meeting, Merck showed patients on the Keytruda regimen lived a … analyst As Roche prepares applications for the use to regulators, SVB Leerink analyst Daina Graybosch has contended it would be hard for Roche to challenge “[t]he lead and loyalty for Keytruda among oncologists treating …

20 Things You Didn’t Know About Innate Pharma SA | 10/29/2019

… information about the IPO The Initial Public Offering for Innate Pharma was led by Citigroup Global Markets, Inc., along with SVB Leerink LLC, and Evercore Group LLC. Together the three participated in the IPO as … member of the European Society of Medical Oncology and the American Society of Clinical Oncology. He was appointed to the executive leadership position of the company near the end of 2016. 18. Mahjoubi brings extensive …

Vivo Capital

Bolt Biotherapeutics Announces Scientific Advisory Board with the Appointment of Drs. Larry Fong, Roy Herbst and Bruce Roth | PR Newswire | 10/8/2019

… Ed Engleman and Mark Davis focused on tumor immunology. He served on the program committees and editorial boards for the American Society of Clinical Oncology (ASCO) and the American Association of Cancer Research (AACR). He … by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com where you will find complete biographies of Bolt’s SAB …

Revolution Medicines snags $100M to attack RAS-mutated cancers | FierceBiotech | 7/10/2019

… obvious binding sites on the KRAS protein. Amgen posted the first clinical data for a KRAS inhibitor at this year’s American Society of Clinical Oncology meeting, showing its drug AMG 510 stopped tumor growth in … Capital of the Tavistock Group, Cormorant Capital, Deerfield Management, Fidelity, Vivo Capital and Biotechnology Value Fund. They were joined by Casdin Capital, The Column Group, Nextech Invest, Schroder Adveq and Third Rock Ventures—which all …

Zacks Equity Research

Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study | Nasdaq | 8/14/2019

Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study August 14, 2019, 12:18:00 PM EDT By Zacks Equity Research, Zacks.com Shutterstock photo Vaccinex, Inc. VCNX announced that it has achieved full enrollment in an early … The outcomes were presented at the annual meeting of the American Society of Clinical Oncology held in June. Shares of Vaccinex have rallied 36.1% so far this year versus the industry’s decrease of 2.1%. We …

J&J Submits BLA for Subcutaneous Formulation of Darzalex | Zacks | 7/16/2019

J&J Submits BLA for Subcutaneous Formulation of Darzalex Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More … of infusion-related reactions. The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting this year. The BLA was also supported by data from the phase II PLEIADES (MMY2040) study, which …

Leukemia & Lymphoma Society

Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome | Globe Newswire | 8/6/2019

Leukemia & Lymphoma Society (LLS), aimed at accelerating the development of 5F9 for the treatment of myelodysplastic syndromes (MDS). Forty Seven presented updated initial data from its Phase 1b clinical study of 5F9 in patients with MDS at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL and 2019 European Hematology Association Annual Meeting in Amsterdam, Netherlands in June 2019, showing an overall response rate (ORR) of 100 …

Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome | Markets Insider | Business Insider | 8/6/2019

Leukemia & Lymphoma Society (LLS), aimed at accelerating the development of 5F9 for the treatment of myelodysplastic syndromes (MDS). Forty Seven presented updated initial data from its Phase 1b clinical study of 5F9 in patients with MDS at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL and 2019 European Hematology Association Annual Meeting in Amsterdam, Netherlands in June 2019, showing an overall response rate (ORR) of 100 …

Casdin Capital

Revolution Medicines snags $100M to attack RAS-mutated cancers | FierceBiotech | 7/10/2019

… obvious binding sites on the KRAS protein. Amgen posted the first clinical data for a KRAS inhibitor at this year’s American Society of Clinical Oncology meeting, showing its drug AMG 510 stopped tumor growth in … Vivo Capital and Biotechnology Value Fund. They were joined by Casdin Capital, The Column Group, Nextech Invest, Schroder Adveq and Third Rock Ventures—which all chipped into Revolution’s B round and came back for more …

Revolution Medicines secures $100M equity round, aiming for hard-to-reach oncology targets | MedCity News | 7/10/2019

Casdin Capital and Third Rock Ventures also joined the round. The company’s pipeline includes programs targeting the KRAS G12C pathway. While long considered undruggable due to the lack of sufficient “pockets” for pharmaceutical agents to penetrate, KRAS G12C was recently validated as a target thanks to data presented at the American Society of Clinical Oncology meeting last month by Amgen for its drug, AMG 510. The Phase I data – mostly …

Biotechnology Value Fund

Revolution Medicines snags $100M to attack RAS-mutated cancers | FierceBiotech | 7/10/2019

… obvious binding sites on the KRAS protein. Amgen posted the first clinical data for a KRAS inhibitor at this year’s American Society of Clinical Oncology meeting, showing its drug AMG 510 stopped tumor growth in … Tavistock Group, Cormorant Capital, Deerfield Management, Fidelity, Vivo Capital and Biotechnology Value Fund. They were joined by Casdin Capital, The Column Group, Nextech Invest, Schroder Adveq and Third Rock Ventures—which all chipped into Revolution’s …

Revolution Medicines secures $100M equity round, aiming for hard-to-reach oncology targets | MedCity News | 7/10/2019

Biotechnology Value Fund joined. Series B investors, including Nextech Invest, Schroder Adveq, The Column Group, Casdin Capital and Third Rock Ventures also joined the round. The company’s pipeline includes programs targeting the KRAS G12C pathway. While long considered undruggable due to the lack of sufficient “pockets” for pharmaceutical agents to penetrate, KRAS G12C was recently validated as a target thanks to data presented at the American Society of Clinical Oncology

Deerfield Management

Revolution Medicines secures $100M equity round, aiming for hard-to-reach oncology targets | MedCity News | 7/10/2019

… but has often been considered unreachable by pharmaceutical means. The Tavistock Group’s Boxer Capital led the round, which Cormorant Capital, Deerfield Management, Fidelity Management & Research, Vivo Capital and Biotechnology Value Fund joined. Series B investors … validated as a target thanks to data presented at the American Society of Clinical Oncology meeting last month by Amgen for its drug, AMG 510. The Phase I data – mostly in patients with non-small …

Revolution Medicines snags $100M to attack RAS-mutated cancers | FierceBiotech | 7/10/2019

… obvious binding sites on the KRAS protein. Amgen posted the first clinical data for a KRAS inhibitor at this year’s American Society of Clinical Oncology meeting, showing its drug AMG 510 stopped tumor growth in … investors, including Boxer Capital of the Tavistock Group, Cormorant Capital, Deerfield Management, Fidelity, Vivo Capital and Biotechnology Value Fund. They were joined by Casdin Capital, The Column Group, Nextech Invest, Schroder Adveq and Third Rock …

Third Rock Ventures

Revolution Medicines secures $100M equity round, aiming for hard-to-reach oncology targets | MedCity News | 7/10/2019

Third Rock Ventures also joined the round. The company’s pipeline includes programs targeting the KRAS G12C pathway. While long considered undruggable due to the lack of sufficient “pockets” for pharmaceutical agents to penetrate, KRAS G12C was recently validated as a target thanks to data presented at the American Society of Clinical Oncology meeting last month by Amgen for its drug, AMG 510. The Phase I data – mostly in patients with …

Revolution Medicines snags $100M to attack RAS-mutated cancers | FierceBiotech | 7/10/2019

… obvious binding sites on the KRAS protein. Amgen posted the first clinical data for a KRAS inhibitor at this year’s American Society of Clinical Oncology meeting, showing its drug AMG 510 stopped tumor growth in … Casdin Capital, The Column Group, Nextech Invest, Schroder Adveq and Third Rock Ventures—which all chipped into Revolution’s B round and came back for more …

The Column Group

Revolution Medicines snags $100M to attack RAS-mutated cancers | FierceBiotech | 7/10/2019

… obvious binding sites on the KRAS protein. Amgen posted the first clinical data for a KRAS inhibitor at this year’s American Society of Clinical Oncology meeting, showing its drug AMG 510 stopped tumor growth in … and Biotechnology Value Fund. They were joined by Casdin Capital, The Column Group, Nextech Invest, Schroder Adveq and Third Rock Ventures—which all chipped into Revolution’s B round and came back for more …

Revolution Medicines secures $100M equity round, aiming for hard-to-reach oncology targets | MedCity News | 7/10/2019

The Column Group, Casdin Capital and Third Rock Ventures also joined the round. The company’s pipeline includes programs targeting the KRAS G12C pathway. While long considered undruggable due to the lack of sufficient “pockets” for pharmaceutical agents to penetrate, KRAS G12C was recently validated as a target thanks to data presented at the American Society of Clinical Oncology meeting last month by Amgen for its drug, AMG 510. The Phase …

Boxer Capital

Revolution Medicines secures $100M equity round, aiming for hard-to-reach oncology targets | MedCity News | 7/10/2019

… a key role in the development of cancers but has often been considered unreachable by pharmaceutical means. The Tavistock Group’s Boxer Capital led the round, which Cormorant Capital, Deerfield Management, Fidelity Management & Research, Vivo Capital … validated as a target thanks to data presented at the American Society of Clinical Oncology meeting last month by Amgen for its drug, AMG 510. The Phase I data – mostly in patients with non-small …

Revolution Medicines snags $100M to attack RAS-mutated cancers | FierceBiotech | 7/10/2019

… obvious binding sites on the KRAS protein. Amgen posted the first clinical data for a KRAS inhibitor at this year’s American Society of Clinical Oncology meeting, showing its drug AMG 510 stopped tumor growth in … drew its financing from a marquee list of investors, including Boxer Capital of the Tavistock Group, Cormorant Capital, Deerfield Management, Fidelity, Vivo Capital and Biotechnology Value Fund. They were joined by Casdin Capital, The Column …

Harvard Medical School

Black men with early-stage prostate cancer can do active surveillance | 11/28/2019

… these men can be monitored through “active surveillance,” the standard of care recommended by national cancer organizations such as the American Society of Clinical Oncology . In this approach, men diagnosed with early-stage disease receive … Francisco; Stanford University; Emory University; Beth Israel Deaconess Medical Center/Harvard Medical School; University of Michigan; University of Texas Health Science Center, San Antonio; Eastern Virginia Medical School; Veterans Affairs Puget Sound Health Care System …

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy | Blood Advances | American Society of Hematology | 11/26/2019

… competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy Division of Hematology, Massachusetts General Hospital, Boston, MA; 2 Harvard Medical School, Boston, MA; and Search for other works by this author on: Harvard … low bleeding risk, and no drug-drug interactions. 9 The American Society of Clinical Oncology (ASCO) recommendations are similar, with a strong recommendation for using initial anticoagulation with LMWH, unfractionated heparin (UFH), fondaparinux, or rivaroxaban …

University of Rochester

A cancer care approach tailored to the elderly may have better results - WHYY | 11/24/2019

… it’s better than the clinician eyeball test,” says Supriya Gupta Mohile, a geriatric oncologist and professor of medicine at the University of Rochester. “If I didn’t do a geriatric assessment and just looked at a … one of the clinical cancer advances of 2012 by the American Society of Clinical Oncology, they are still not widely used by oncologists. The Surgical Task Force at the International Society of Geriatric Oncology found …

Cleveland Clinic

Lung cancer survival improving | 11/23/2019

… guideline was issued in 2013 by the U.S. Preventive Services Task Force, a government-funded panel of medical experts. The American Society of Clinical Oncology has similar recommendations. Yet in 2018, the ALA report found … lung cancer expert with ASCO. Pennell, who practices at the Cleveland Clinic in Ohio, was not involved in the report. He pointed to an additional reason for the low screening rate: the public’s generally fatalistic …

James Everett Carinder, DO, FACP, a Hematologist and Oncologist with Northshore Oncology Associates | 11/19/2019

… of Osteopathic Medicine in Tulsa, Oklahoma. Pursuing advanced medical training, he completed both his residency and fellowship training at the Cleveland Clinic Foundation. Thereafter, he became board-certified in hematology and medical oncology by the … American Medical Association, the American Society of Hematology, and the American Society of Clinical Oncology. He is also a Fellow of the American College of Physicians. Hematology is the branch of medicine concerned with the …

University of Texas MD Anderson Cancer Center

Secondary surgery does not improve overall survival for recurrent ovarian cancer patients | 11/14/2019

University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer. The Phase III Gynecologic Oncology Group (GOG)-0213 trial results were published today in the New England Journal of Medicine . Early results from this study were first presented at the 2018 American Society of Clinical …

The University of Texas MD Anderson Cancer Center

Secondary surgery does not improve overall survival for recurrent ovarian cancer patients | 11/14/2019

The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer. The Phase III Gynecologic Oncology Group (GOG)-0213 trial results were published today in the New England Journal of Medicine . Early results from this study were first presented at the 2018 American Society of …

Massachusetts General Hospital

Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board – Company Announcement - FT.com | Financial Times | 11/5/2019

… again.” Dr. Lynch has more than 30 years of medical, management and leadership experience, including more than 23 years at Massachusetts General Hospital (MGH) where he served as Chairman and CEO of Massachusetts General Physicians … a member of the American Association for Cancer Research , the American Society of Clinical Oncology , and the International Association for the Study of Lung Cancer . He is on the editorial boards of the journal, Clinical …

HCA

ASCO President’s Thoughts on Conquering Cancer: Unite : Oncology Times | 11/5/2019

Howard “Skip” Burris III, MD, FACP, FASCO Though famous for walking his dog in his Tennessee neighborhood, in professional circles Howard “Skip” Burris III, MD, FACP, FASCO, is President and Chief Medical Officer for Sarah Cannon, the Cancer Institute of HCA Healthcare, in Nashville, and current President of the American Society of Clinical Oncology (ASCO). While eager to discuss ASCO and his goals as president, Burris first explained that he …

University of Nebraska Medical Center

Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors | Journal of Oncology Practice | 11/5/2019

… American Society of Clinical Oncology, Alexandria, VA 3 US Food and Drug Administration, Silver Spring, MD 4 Sarah Cannon Cancer Center, Nashville, TN 5 Bristol-Myers Squibb, New York, NY 6 University of Nebraska Medical Center, Omaha, NE Abstract PURPOSE: Investigators often send reports to sponsors that incorrectly categorize adverse event (AE)s as serious or attribute AEs to investigational drugs. Such errors can contribute to high volumes of uninformative …

Healthcare Times - News - Cancer Research | 10/31/2019

… modifiable risk factors for prevention,” said lead author Corrine Hanson PhD, RD, an associate professor of medical nutrition at the University of Nebraska Medical Center. “However, beyond smoking very few preventative strategies have been identified … Translational Medicine. The study was funded in part by an American Society of Clinical Oncology Advanced Clinical Research Award to Kirsch, the National Institutes of Health (NIH) (T32GM007171), a National Cancer Institute Small Business Innovation …

MD Anderson Cancer Center

Trump Taps Cancer Specialist From Texas Hospital to Run FDA | 11/2/2019

… handle the Food and Drug Administration. As per the information, if it is true, then Dr Stephen Hahn, working at MD Anderson Cancer Center as the Chief Medical Executive, located in Houston, will manage the … located in Philadelphia. He is also a member of “the American Society of Clinical Oncology, Radiation Research Society, and more. SHARE …

Trump nominates MD Anderson oncologist as U.S. FDA Commissioner | 11/1/2019

… Beasley (Reuters) - U.S. President Donald Trump plans to nominate Dr. Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration, the White House said … medicines and medical devices. Hahn’s nomination was lauded by the American Society of Clinical Oncology and the American Association for Cancer Research, which said in a statement it was “extremely confident that he will be …

Mayo Clinic

October 2019 Briefing - Internal Medicine | 11/1/2019

… Only one in four U.S. adults report incorporating cancer prevention into their daily lives, according to the results of the American Society of Clinical Oncology 2019 National Cancer Opinion Survey. More Information Hypoglycemia Increases Risk … cardiovascular events, according to research published online Oct. 23 in Mayo Clinic Proceedings . Abstract/Full Text (subscription or payment may be required) One Lot of Generic Form of Xanax Recalled Due to Potential Contaminate MONDAY …

Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference Swiss Stock Exchange:BSLN | Globe Newswire | 10/30/2019

… study in patients with advanced urothelial cancer. 1 A second abstract presented data obtained in collaboration with Dr. Jann Sarkaria (Mayo Clinic, Rochester), demonstrating significant survival benefits in patient-derived glioblastoma models after treatment with … with progressive or recurrent glioblastoma (GBM) or high-grade glioma. American Society of Clinical Oncology (ASCO) annual meeting 2019, abstract 2025; Journal of Clinical Oncology 2019, 37 (15 supplement), 2025 7 T. G. Hall, Y …

Health Net

Another physician shortage: oncologists | FierceHealthcare | 10/30/2019

… women, making access to treatment a key concern for women’s healthcare. The demand for cancer treatment is expected to grow by 40% over the next six years, while at the same time, the American Society of Clinical Oncology is projecting a shortage of more than 2,200 oncologists by 2025. RELATED: In high stakes business, oncologists subject to more burnout “Cancer is one of the most pressing health issues that women …

New Study Shows Growing Shortage of U.S. Oncologists Poses Risks to Women’s Health | PR Newswire | 10/30/2019

… nationally. MSAs with the highest risk of an oncologist shortage. The demand for cancer treatment is expected to grow by 40 percent over the next six years and at the same time, the American Society of Clinical Oncology (ASCO) is projecting a shortage of more than 2,200 oncologists over the next six years 2 . The “ 2019 Women’s Health and Oncologist Workforce Analysis “ asses which U.S. metropolitan statistical areas (MSAs) will …

Andrew Krivoshik

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… and we are committed to studying enfortumab vedotin in combination with other agents in different stages of urothelial cancer,” said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head at Astellas. “We … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Malvern Daily Record | 12/2/2019

… and we are committed to studying enfortumab vedotin in combination with other agents in different stages of urothelial cancer,” said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head at Astellas. “We … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Kenji Yasukawa

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… TOKYO–(BUSINESS WIRE)–Dec 2, 2019– Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Malvern Daily Record | 12/2/2019

Seattle Genetics, Inc. ( Nasdaq:SGEN ) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Roger Dansey

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… forward to initiating a randomized phase 3 trial in patients with previously untreated locally advanced or metastatic urothelial cancer,” said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. “Recent data from a phase 1b … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Malvern Daily Record | 12/2/2019

… forward to initiating a randomized phase 3 trial in patients with previously untreated locally advanced or metastatic urothelial cancer,” said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. “Recent data from a phase 1b … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Fred Hutchinson

Black men with early-stage prostate cancer can do active surveillance | 11/28/2019

… Urology , comes from a large research collaboration known as the Canary Prostate Active Surveillance Study, or Canary PASS , led by Fred Hutchinson Cancer Research Center. “I think this is good news for African American men … of care recommended by national cancer organizations such as the American Society of Clinical Oncology . In this approach, men diagnosed with early-stage disease receive regular PSA (prostate-specific antigen) testing, biopsies and digital-rectal …

Integrating Value Into Pathways: Fred Hutchinson’s Approach | 10/9/2019

Integrating Value Into Pathways: Fred Hutchinson’s Approach October 09, 2019 In a presentation at the American Society of Clinical Oncology (ASCO) Quality Care Symposium (September 7, 2019; San Diego, CA), Scott D Ramsey, MD, PhD, director of the Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, presented on integrating value into clinical pathways. Journal of Clinical Pathways discussed with Dr Ramsey some of the challenges of assessing …

Saiid Zarrabian

DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM | PR Newswire | 11/25/2019

… very intriguing and exciting. Obviously, we need to see the completed data and then move on to the next steps.” Saiid Zarrabian , CEO of DelMar Pharmaceuticals stated: “ We continue to be encouraged with the interim … in 2020 at the American Association for Cancer Research and American Society of Clinical Oncology conferences.” The Company’s current cash resources are expected to be sufficient to fund the Company’s planned operations into the fourth …

/C O R R E C T I O N – DelMar Pharmaceuticals, Inc./ - GuruFocus.com | 11/25/2019

… very intriguing and exciting. Obviously, we need to see the completed data and then move on to the next steps.” Saiid Zarrabian , CEO of DelMar Pharmaceuticals stated: “ We continue to be encouraged with the interim … in 2020 at the American Association for Cancer Research and American Society of Clinical Oncology conferences.” The Company’s current cash resources are expected to be sufficient to fund the Company’s planned operations into the fourth …

Eliran Malki

Belong.Life Expands to South Africa, Broadens Global Impact | PR Newswire | 11/20/2019

American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). “While breast cancer is common all around the world, gaps in education, lack of support and access to medical professionals persist,” said Eliran Malki , co-founder and CEO of Belong.Life. “We are thrilled to expand our footprint to South Africa with our distinguished partners, BHF and The Pink Parasol Project, as they join our growing list …

Belong.Life: New Study Shows Advanced Breast Cancer Patients in the US Cite Copayments as Main Financial Burden | PR Newswire | 11/15/2019

… methods. “This vital study demonstrates the importance of engaging medical patients to understand the full scope of disease burden,” said Eliran Malki , CEO and Co-Founder of Belong.Life. “Currently published data tends to focus on … collaborates with leading universities and has published research with The American Society of Clinical Oncology (ASCO) and other organizations. Website: https://belong.life/ Follow Belong on Facebook , Twitter and LinkedIn . Media Contact: Ellie Hanson Finn Partners …

Luciano Rossetti

Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations | PR Newswire | 11/20/2019

… MET gene alterations. “Advanced NSCLC harboring MET gene alterations is associated with aggressive tumor behavior and poor clinical prognosis,” said Luciano Rossetti , Global Head of Research & Development for the Biopharma business of Merck KGaA, Darmstadt … study were presented in an oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting 6 and the 2019 Japan Society of Medical Oncology (JSMO) Annual Meeting. 7 The use of both …

Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations | Benzinga | 11/20/2019

… MET gene alterations. “Advanced NSCLC harboring MET gene alterations is associated with aggressive tumor behavior and poor clinical prognosis,” said Luciano Rossetti , Global Head of Research & Development for the Biopharma business of Merck KGaA, Darmstadt … study were presented in an oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting 6 and the 2019 Japan Society of Medical Oncology (JSMO) Annual Meeting. 7 The use of both …

Craig Tendler

Janssen Receives EU Marketing Authorisation for Darzalex®▼(daratumumab) in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible | Business Wire | 11/19/2019

… option available to them,” said Dr Patrick Laroche, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag. Craig Tendler, M.D., Vice President, Clinical Development and Global Medical Affairs, Oncology, Janssen Research & Development … investigational-anti-cancer-agent-daratumumab Last accessed November 2019. 18 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/introduction Last accessed November 2019. 19 GLOBOCAN 2018. Cancer …

Richard Pazdur

FDA Approves Crizanlizumab-tmca for Sickle Cell Disease | 11/15/2019

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients … the Director of the FDA Oncology Center of Excellence , Dr. Richard Pazdur: On November 15, 2019, the Food and Drug Administration approved crizanlizumab-tmca (ADAKVEO, Novartis) to reduce the frequency of vaso-occlusive crises (VOCs …

Here’s Why Only 2% of Cancer Patients Survive 5 Years After Chemo | 11/9/2019

… its officials don’t seem to have anything against the lack of current evidence when it comes to survival improvement. Dr. Richard Pazdur, the director of FDA’s Oncology Center of Excellence, stated that cancers could grow … the senior vice president and chief medical officer of the American Society of Clinical Oncology, Dr. Richard Schilsky says that there is no undermining the progress made so far. There has been quite the commotion …

Robert L. Coleman

Secondary surgery does not improve overall survival for recurrent ovarian cancer patients | 11/14/2019

… not improve overall survival for recurrent ovarian cancer patients 12-Nov-2019 10:00 AM EST Credit: MD Anderson Cancer Center Robert L. Coleman, M.D. Available for logged-in reporters only CITATIONS MD Anderson Cancer Center … results from this study were first presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The overall survival (OS) was 50.6 months in the surgery group and 64.7 months in the no …